Eli Lilly has shared one-year histologic outcomes from a phase 3 study of its interleukin-23p19 antagonist mirikizumab in ...

A US Food and Drug Administration (FDA) panel of experts has voted in support of Stealth BioTherapeutics’ elamipretide for ...

Up to 20% of patients will develop metastatic castration-resistant disease within five to seven years of diagnosis ...

Patient Recruitment company, Innovative Trials, appointed new Finance and Business Services Director Innovative Trials have ...

Johnson & Johnson (J&J) has announced results from a real-world study comparing its Erleada (apalutamide) to Pfizer and ...

Astellas Pharma and AviadoBio have entered into an exclusive option and licence agreement worth over $2bn for an ...

What clinical and economic evidence do US payers prefer to drive formulary decisions? How can you optimise your chances of ...

AstraZeneca (AZ) has entered into an exclusive licence agreement worth over $1.9bn to advance CSPC Pharmaceutical Group’s pre-clinical lipid-lowering therapy, strengthening the Anglo-Swedish drugmaker ...

• Mtech Access – Powered by Petauri™ are excited to be returning to ISPOR Europe this November. The team will be joined by ...

Merck & Co – known as MSD outside the US and Canada – has shared positive results from a late-stage study of its anti-PD-1 therapy in head and neck cancer. The phase 3 KEYNOTE-689 trial has been ...

AbbVie has shared positive top-line results from a late-stage study of its investigational Parkinson’s disease (PD) drug in adults. The phase 3 TEMPO-1 trial evaluated two fixed doses of the D1/D5 ...

Eli Lilly has partnered with insitro to advance new treatments for metabolic diseases, including metabolic dysfunction-associated steatotic liver disease (MASLD). The new drugs developed under the ...